Back to MRKView full pipeline
Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
Drug Information
Patent & Exclusivity
ActiveRLD
Latest Patent Expiry
Jul 26, 2029(2y 10m)
Patents Listed
1
Exclusivity
ODE-324
Application
NDA 213969Regulatory Approvals
EMA7/18/2022
Zokinvy
Zokinvy is indicated for the treatment of patients 12 months of age and older with a genetically confirmed diagnosis of Hutchinson-Gilford progeria syndrome or a processing-deficient progeroid laminopathy associated with either a heterozygous LMNA mutation with progerin-like protein accumulation or a homozygous or compound heterozygous ZMPSTE24 mutation.
Orphan
View on EMADrug Science
Mechanism of action & safety profile
Related Pipeline
MK-8748Phase 3
Diabetic Retinopathy
alendronate with cholecalciferolPhase 3
Osteoporosis
Simvastatin 20 mg dailyPhase 3
Cardiovascular Disease
EpinephrinePhase 3
Malignant Neoplasms of Male Genital Organs
9 valent human papillomavirus vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)Phase 3
HPV Positive Oropharyngeal Squamous Cell Carcinoma
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts